934
Chapter 33
245. Piera JM, Alonso MC, Ojeda MB, et al. Locally advanced breast cancer
with inflammatory component: a clinical entity with a poor prognosis.
Radiother Oncol
1986;7:199–204.
246. Kokal WA, Hill RL, Porudominsky D, et al. Inflammatory breast car
cinoma: a distinct entity?
J Surg Oncol
1985;30:152–155.
247. Anderson WF, Chuk C, Chang S. Inflammatory breast carcinoma and
noninflammatory locally advanced breast carcinoma: distinct clinico
pathologic entities.
J Clin Oncol
2003;21:2254–2259.
248. Charpin C, Bounier P, Khouzami A, et al. Inflammatory breast carci
noma: an immunohistochemical study usingmonoclonal anti-pHER-2/
neu, pS2, cathepsin, ER and PR.
Anticancer Res
1992;12:591–598.
249. Guerin M, Gabillot M, Mathieu M-C, et al. Structure and expres
sion of c-erbB-2 and EGF receptor genes in inflammatory and non-
inflammatory breast cancer: prognostic significance.
Int J Cancer
1989;43:201–208.
250. Schäfer P, Alberto P, Forni M, et al. Surgery as part of a combined
modality approach for inflammatory breast carcinoma.
Cancer
1987;59:1063–1067.
251. Gong Y. Pathologic aspects of inflammatory breast cancer: part 2.
Biologic insights of its aggressive phenotype.
Semin Oncol
2008;
35:33–40.
252. Alpaugh ML, Tomlinson JS, Shao ZM, et al. A novel human xenograft
model of inflammatory breast cancer.
Cancer Res
1999;59:5079–5084.
253. Resetkova E, Gonzalez-Angulo AM, Sneige N, et al. Prognostic value
of P53, MDM-2, and MUC-1 for patients with inflammatory breast
carcinoma.
Cancer
2004;101:913–917.
254. Riou G, Le MG, Travagli JP, et al. Poor prognosis of p53 gene muta
tion and nuclear overexpression of p53 protein in inflammatory breast
carcinoma.
J Natl Cancer Inst
1993;85:1765–1767.
255. Turpin E, Bieche I, Bertheau P, et al. Increased incidence of ERBB2
overexpression and TP53 mutation in inflammatory breast cancer.
Oncogene
2002;21:7593–7597.
256. Charafe-Jauffret E, Tarpin C, Bardou V-J, et al. Immunophenotypic
analysis of inflammatory breast cancers: identification of an inflam
matory signature.
J Pathol
2004;202:265–273.
257. Vincent-Salomon A, Jouve M, Genin P, et al. HER2 status in patients
with breast carcinoma is not modified selectively by preoperative
chemotherapy and is stable during the metastatic process.
Cancer
2002;94:2169–2173.
258. Arens N, Bleyl U, Hildenbrand R. HER2/neu, p53, Ki67 and hormone
receptors do not change during neoadjuvant chemotherapy in breast
cancer.
Virchows Arch
2005;446:489–496.
259. McCarthy NJ, Yang X, Linnoila IR, et al. Microvessel density, expres
sion of estrogen receptor alpha, MIB-1, p53 and c-erbB-2 in inflam
matory breast cancer.
Clin Cancer Res
2002;8:3857–3862.
260. Colpaert CG, Vermeulen PB, Benou I, et al. Inflammatory breast can
cer shows angiogenesis with high endothelial proliferation rate and
strong E-cadherin expression.
Br J Cancer
2003;88:718–725.
261. Bioche I, Lereboure F, Tozlu S, et al. Molecular profiling of inflamma
tory breast cancer” Identification of a poor-prognosis gene expression
signature.
Clin Cancer Res
2004;10:6789–6795.
262. Kleer CG, vanGolen KL, Merajver SD. Molecular biology of breast
cancer metastasis. Inflammatory breast cancer: clinical syndrome and
molecular determinants.
Breast Cancer Res
2000;2:423–429.
263. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor
effects of bevacizumab in patients with inflammatory and locally ad
vanced breast cancer.
J Clin Oncol
2006;24:769–777.
264. Guth U, Moch H, Herberich L, et al. Noninflammatory breast carci
noma with skin involvement. Clinical diagnosis is relevant to appro
priate classification in the TNM system.
Cancer
2004;1000:470–478.
265. Tschen EH, Apisarnthanarax P. Inflammatory metastatic carcinoma
of the breast.
Arch Dermatol
1981;177:120–121.
266. Brownstein MH, Helwig EB. Spread of tumors to the skin.
Arch Der-
matol
1973;107:80–86.
267. Hazelrigg DC, Rudolph AH. Inflammatory metastatic carcinoma.
Arch Dermatol
1977;113:69–70.
268. Meyer AC, Dockerty MB, Harrington SW. Inflammatory carcinoma
of the breast.
Surg Gynecol Obstet
1948;87:417–424.
269. Lucas FV, Perez-Mesa C. Inflammatory carcinoma of the breast.
Can-
cer
1978;41:1595–1605.
270. Kumar N, Sayed S, Moloo Z, et al. Fine-needle aspiration in suspected
inflammatory breast cancer: case series with emphasis on approach to
specimen adequacy.
Acta Cytol
2011;55:239–244.
216. Velanovich V. Fine needle aspiration cytology in the diagnosis and
management of ectopic breast tissue.
Am Surg
1995;61:277–278.
217. Vargas J, Nevado M, Rodríguez-Peralto J, et al. Fine needle aspiration
diagnosis of carcinoma arising in an ectopic breast. A case report.
Acta
Cytol
1995;39:941–944.
218. Paksoy N. Ectopic lesions as potential pitfalls in fine needle aspiration
cytology: a report of 3 cases derived from the thyroid, endometrium
and breast.
Acta Cytol
2007;51:222–226.
Inflammatory Carcinoma
219. Bell C.
A systemof operative surgery,
vol. 1. London: Longman, 1807:180.
220. Lee BJ, Tannenbaum E. Inflammatory carcinoma of the breast: a re
port of twenty-eight cases from the breast clinic of the Memorial Hos
pital.
Surg Gynecol Obstet
1924;39:580–595.
221. Edge SB, Byrd DR, Compton CC, et al., eds.
AJCC Cancer Staging
Manual
. 7th ed. New York: Springer, 2009:354–355.
222. Robertson FM, Bondy M, Yang W, et al. Inflammatory breast
cancer: the disease, the biology, the treatment.
CA Cancer J Clin
2010;60:351–375.
223. Ellis DL, Teitelbaum SL. Inflammatory carcinoma of the breast. A
pathologic definition.
Cancer
1974;33:1045–1047.
224. Saltzstein SL. Clinically occult inflammatory carcinoma of the breast.
Cancer
1974;34:382–388.
225. Levine PH, Steinhorn SC, Ries LG, et al. Inflammatory breast can
cer: the experience of the surveillance, epidemiology, and end results
(SEER) program.
J Natl Cancer Inst
1985;74:291–297.
226. Chang S, Parker SL, Pham T, et al. Inflammatory breast carcinoma inci
denceandsurvival:thesurveillance,epidemiology,andendresultsprogram
of the National Cancer Institute, 1975–1992.
Cancer
1998;82:2366–2372.
227. Il’yasova D, Siamakpour-Reihani S, Akushevich I, et al. What can we
learn from the age- and race/ethnicity- specific rates of inflammatory
breast carcinoma?
Breast Cancer Res Treat
2011;130:691–697.
228. Boussen H, Bouzaiene H, Ben Hassouna J, et al. Inflammatory
breast cancer in Tunisia: epidemiological and clinical trends.
Cancer
2010;116(11 Suppl.):2730–2735.
229. Chamadol W, Pesie M, Puapairoj A. Inflammatory carcinoma of the
breast in a 12 year old Thai girl.
J Med Assoc Thai
1987;70:543–547.
230. Nichini F, Holdman L, Lapayowker M, et al. Inflammatory carcinoma
of the breast in a 12-year-old girl.
Arch Surg
1972;105:505–508.
231. Treves N. Inflammatory carcinoma of the breast in a male patient.
Surgery
1953;34:810–820.
232. Haagensen CD. Inflammatory carcinoma. In:
Diseases of the breast
,
2nd ed. Philadelphia: WB Saunders, 1971:576–584.
233. Stocks L, Patterson S. Inflammatory carcinoma of the breast.
Surg
Gynecol Obstet
1976;143:885–889.
234. Robbins GF, Shah J, Rosen P, et al. Inflammatory carcinoma of the
breast.
Surg Clin N Am
1974;54:801–810.
235. Barker JL, Nelson AJ III, Montague ED. Inflammatory carcinoma of
the breast.
Radiology
1976;121:173–176.
236. Droulias CA, Sewell CW, McSweeney MB, et al. Inflammatory carci
noma of the breast. A correlation of clinical radiologic and pathologic
findings.
Ann Surg
1976;184:217–222.
237. Nussbaum H, Kagan AR, Gilbert H, et al. Management of inflamma
tory breast carcinoma.
Breast
1977;3:25–28.
238. Dershaw DD, Moore MP, Liberman L, et al. Inflammatory breast car
cinoma: mammographic findings.
Radiology
1994;190:831–834.
239. Tardivon AA, Viala J, Rudelli AC, et al. Mammographic patterns of
inflammatory breast carcinoma: a retrospective study of 92 cases.
Eur
J Radiol
1997;24:124–130.
240. Kushwaha AC, Whitman GJ, Stelling CB, et al. Primary inflammatory
carcinoma of the breast: retrospective review of mammographic find
ings.
AJR Am J Roentgenol
2000;174:535–538.
241. Gunhan-Bilgen I, Ustun EE, Memis A. Inflammatory breast carci
noma: mammographic, ultrasonographic, clinical and pathologic
findings in 142 cases.
Radiology
2002;223:829–838.
242. Shukla HS, Hughes LE, Gravelle IH, et al. The significance of mam
mary skin edema in noninflammatory breast cancer.
Ann Surg
1979;89:53–57.
243. Le-Petross CH, Bidaut L, Yang WT. Evolving role of imaging modali
ties in inflammatory breast cancer.
Semin Oncol
2008;35:51–63.
244. Le-Petross HT, Cristofanilli M, Carkaci S, et al. MRI features of inflam
matory breast cancer.
AJR Am J Roentgenol
2011;197:W769–W776.
